Core Viewpoint - WORK Medical Technology Group LTD will implement a reverse stock split of its ordinary shares on a 1-for-100 basis to comply with Nasdaq Marketplace Rule 5550(a)(2) regarding minimum bid price requirements [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will take effect on December 29, 2025, with Class A ordinary shares trading under the symbol "WOK" and a new CUSIP number G9767H125 [1]. - The reverse stock split has been approved by both the Company's shareholders and board of directors [2]. - Every 100 shares of Class A and Class B ordinary shares will be combined into one share, and fractional shares will be rounded up to the next whole number [3][4]. Group 2: Company Overview - WORK Medical Technology Group LTD, through its subsidiary, is a supplier of medical devices in China, developing and manufacturing Class I and II medical devices [5]. - The company has a diverse product portfolio of 21 products, including customized masks and medical consumables, sold in 34 provincial-level regions in China and over 30 countries worldwide [5]. - The company has received multiple quality-related manufacturing designations and has registered 17 products with the U.S. Food and Drug Administration for entry into the U.S. market [5].

Core Viewpoint - Birchtech Corp. has announced a 1-for-5 reverse stock split to enhance the marketability of its shares and support its strategic and capital market initiatives [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will be effective on December 26, 2025, with trading on a split-adjusted basis starting December 31, 2025 [1]. - Every five shares of common stock will be combined into one share, with no fractional shares issued; any fractions will be rounded up to the next whole share [4]. - The company's trading symbol will remain unchanged, but a "D" will be temporarily added for 20 business days on the OTCQB [3]. Group 2: Strategic Intentions - The reverse stock split aims to increase the share price, improve marketability, and position the company for future strategic opportunities [2]. - The company believes that this move will unlock access to a larger pool of institutional capital, enhancing liquidity and broadening its reach [5]. Group 3: Company Overview - Birchtech Corp. specializes in activated carbon technologies for air and water treatment, focusing on sustainable solutions [5]. - The company is recognized for its patented SEA® sorbent technologies for mercury emissions capture and is developing innovative water purification technologies targeting forever chemicals like PFAS and PFOS [5].

Core Viewpoint - Birchtech Corp. has announced a 1-for-5 reverse stock split to enhance the marketability of its shares and support its strategic and capital market initiatives [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will be effective on December 26, 2025, with trading on a split-adjusted basis starting December 31, 2025 [1]. - Every five shares of common stock will be combined into one share, with no fractional shares issued; any fractions will be rounded up to the next whole share [4]. - The trading symbol will remain unchanged, but a "D" will be temporarily added for 20 business days on the OTCQB [3]. Group 2: Strategic Intentions - The reverse stock split aims to increase the share price, improve marketability, and position the company for future strategic opportunities [2]. - The company believes this action will unlock access to a larger pool of institutional capital, enhancing liquidity and broadening its market reach [5]. Group 3: Company Overview - Birchtech Corp. specializes in activated carbon technologies for air and water treatment, focusing on sustainable solutions [5]. - The company is recognized for its patented SEA® sorbent technologies for mercury emissions capture and is developing innovative water purification technologies targeting forever chemicals like PFAS and PFOS [5].

Core Viewpoint - Can-Fite BioPharma Ltd. has announced a 1-for-3,000 reverse split of its ordinary shares, which will take effect on January 2, 2026, with the first trading of the consolidated shares on January 5, 2026 [1][4]. Share Structure Changes - Each outstanding 3,000 pre-split ordinary shares will combine into one new ordinary share automatically, with no action required from shareholders [2]. - The ratio of ordinary shares underlying the Company's American Depositary Shares (ADSs) will change from 1 ADS representing 300 ordinary shares to 1 ADS representing 2 ordinary shares, effective January 5, 2026 [2][3]. - The total number of outstanding ordinary shares will decrease from 42 billion to 14 million as a result of the reverse split [4]. Impact on ADS Holders - For ADS holders, the ratio change equates to a one-for-twenty ADS split, requiring the exchange of every 20 ADSs for one new ADS [3]. - No fractional new ADSs will be issued; instead, fractional entitlements will be aggregated and sold, with net cash proceeds distributed to ADS holders [6]. Ownership and Voting Power - The reverse split and ADS ratio change will not affect shareholders' percentage ownership or voting power, aside from minimal effects from fractional shares [5]. Market Expectations - The ADS price is expected to increase proportionally due to the change in the ADS ratio, although there is no assurance that the price will be equal to or greater than twenty times the pre-split price [7]. Company Overview - Can-Fite BioPharma Ltd. is focused on developing small-molecule drugs for oncological and inflammatory diseases, with its lead drug candidate, Piclidenoson, in Phase III trials for psoriasis [8]. - The company is also advancing Namodenoson, which is in various stages of trials for liver cancer and has received Orphan Drug Designation in the U.S. and Europe [8].

Core Viewpoint - SeaStar Medical Holding Corporation announced a 1-for-10 reverse stock split effective January 5, 2026, to increase its stock price and regain compliance with Nasdaq's minimum bid price requirement of $1.00 [1][4]. Group 1: Reverse Stock Split Details - The reverse stock split will convert every 10 pre-split shares into 1 post-split share, with stockholders receiving whole shares in lieu of any fractional shares [2]. - The reverse split will proportionately reduce the number of shares issuable upon the exercise of outstanding stock options and warrants, while also increasing their exercise prices accordingly [2]. Group 2: Stockholder Information - Stockholders will receive information regarding their share ownership from Continental Stock Transfer and Trust Company following the reverse stock split [3]. - Those holding shares through banks or brokers will have their positions automatically adjusted without needing further action [3]. Group 3: Company Overview - SeaStar Medical is focused on transforming treatments for critically ill patients facing organ failure, with its first commercial product, QUELIMMUNE (SCD-PED) therapy, approved by the FDA in 2024 for life-threatening acute kidney injury in pediatric patients [5]. - The company is conducting the NEUTRALIZE-AKI pivotal trial for its SCD therapy in adult patients, addressing a significant unmet medical need affecting over 200,000 adults in the U.S. annually [5].

Core Viewpoint - Baiya International Group Inc. is implementing a reverse stock split to meet Nasdaq listing requirements, specifically to maintain a minimum bid price of $1.00 per share [2]. Group 1: Reverse Stock Split Details - The reverse stock split will occur at a ratio of 1-for-25, changing the par value of the ordinary shares from $0.0001 to $0.0025 [1]. - The effective date for the reverse stock split is set for December 29, 2025, at 04:01 p.m. (ET), with trading on a split-adjusted basis commencing on December 30, 2025 [3]. - The number of outstanding shares will decrease from approximately 29,644,605 to about 1,185,784 shares, with no fractional shares being issued [4]. Group 2: Shareholder Impact - Shareholders holding ordinary shares in book-entry form or through intermediaries will not need to take any action, as the reverse stock split will be automatically reflected in their accounts after December 30, 2025 [5].

Core Viewpoint - ECD Automotive Design, Inc. will implement a 1-for-5 reverse stock split effective December 26, 2025, to increase its stock price and meet Nasdaq listing requirements [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will convert every five pre-split shares into one share, reducing the total outstanding shares from approximately 6,925,006 to about 1,385,002 [3]. - The reverse stock split was approved by stockholders on July 22, 2025, with the final ratio determined by the Board of Directors [2]. - The reverse stock split will not affect the number of authorized shares or the par value of the common stock [3]. Group 2: Shareholder Information - Shareholders holding shares in book-entry form will not need to take action to receive post-split shares, while those with certificated shares will receive instructions from the transfer agent [4]. - No fractional shares will be issued; instead, fractional shares will be rounded up to the nearest whole share [4]. Group 3: Company Overview - ECD is the largest Land Rover and Jaguar restoration company, known for custom luxury builds, including bespoke Defenders and Range Rovers [6]. - Founded in 2013, ECD combines classic vehicle aesthetics with modern performance, employing master-certified craftsmen [6]. - The company's headquarters, the "Rover Dome," spans 100,000 square feet in Kissimmee, Florida, housing 87 staff members, including 67 craftsmen with a total of 66 ASE certifications [6].

Core Viewpoint - ConnectM Technology Solutions, Inc. is seeking stockholder approval for a reverse stock split in the range of 1-for-5 to 1-for-50 to align with its plans for uplisting to a U.S. national securities exchange, aiming to enhance corporate visibility and shareholder value [1][2]. Group 1: Reverse Stock Split Details - The proposed reverse stock split will be within a range of 1-for-5 to 1-for-50, with the exact ratio to be determined by the Board [1][2]. - The reverse split is intended to support the company's strategy and application for uplisting, which is expected to increase liquidity and awareness in the financial community [2][4]. - The previous stockholder approval for a narrower reverse split range of 1-for-5 to 1-for-8 was not implemented, and the Board is now seeking broader authority [2][3]. Group 2: Effects of the Reverse Split - If approved, the reverse split will not change the overall value of the stock; the market price per share will increase proportionately with the reduction in the number of shares [5]. - Each stockholder's number of shares will be reduced proportionately based on the final split ratio, with fractional shares rounded up to the nearest whole share [5]. - The reverse split will not alter the par value of the common stock or the rights of stockholders, and it will be subject to regulatory review [3][5]. Group 3: Strategic Intent - The uplisting process and reverse split are viewed as tools to align the capital markets profile with the scale of the business, making ConnectM accessible to a broader base of long-term, high-quality investors [4]. - The company is focused on strengthening its balance sheet, simplifying its capital structure, and building a differentiated energy and AI platform through its subsidiaries [2][4]. Group 4: Company Overview - ConnectM Technology Solutions, Inc. operates in the modern energy economy, providing AI-powered electrification, distributed energy, last-mile delivery, and industrial IoT solutions globally [7].

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 19, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MOMENTUS INC. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) Delaware 3714 84-1905538 (I.R.S. Employer Identification Number) 3901 N ...

Core Viewpoint - 374Water Inc. has announced a reverse stock split of 1-for-10 to comply with Nasdaq listing rules and enhance its market appeal, alongside leadership changes and stock purchases by management [3][5][4]. Leadership Changes - Stephen J. Jones has been appointed as Chairperson of the Board of Directors, replacing Rene Estes, and he continues as Interim President and CEO [1][4]. - James Pawlowski has been appointed as Lead Independent Director [1]. Stock Purchase Activity - Stephen J. Jones completed an open market purchase of 450,000 shares of 374Water common stock, with additional purchases made by other management members [2][4]. Reverse Stock Split Details - The reverse stock split was approved at the special meeting of stockholders on December 15, 2025, and will take effect on December 26, 2025 [3][6]. - The split aims to maintain compliance with Nasdaq's minimum bid price requirement and attract a broader range of institutional and retail investors [5][6]. Company Overview - 374Water Inc. is a leader in organic waste destruction technology, providing solutions for wastewater treatment and waste management across industrial, municipal, and federal markets [7]. - The company's AirSCWO technology efficiently destroys a wide range of organic wastes, producing safe dischargeable water and recoverable heat energy [7].